Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning (Review)

Oncology Letters

Volumn 11, Issue 2, 2016, Pages 1287-1293

  Irie, Haruko ^a   Banno, Kouji ^a   Yanokura, Megumi ^a   Iida, Miho ^a   Adachi, Masataka ^a   Nakamura, Kanako ^a   Umene, Kiyoko ^a   Nogami, Yuya ^a   Masuda, Kenta ^a   Kobayashi, Yusuke ^a   Tominaga, Eiichiro ^a   Aoki, Daisuke ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Breast cancer; Drug repositioning; Endometrial cancer; Metformin; Ovarian cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MEDROXYPROGESTERONE ACETATE; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN S6; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR E2F1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; DISEASE SPECIFIC SURVIVAL; DRUG EFFICACY; DRUG REPOSITIONING; ENDOMETRIUM CANCER; ENZYME INHIBITION; FEMALE GENITAL TRACT CANCER; GENE EXPRESSION REGULATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY CANCER; OVARY POLYCYSTIC DISEASE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; UTERINE CERVIX CANCER;

EID: 84954350249     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4075     Document Type: Article

References (70)

1. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R and Zinman B; Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes: Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49: 1711-1721, 2006.
2. Aljada A and Mousa SA: Metformin and neoplasia: Implications and indications. Pharmacol Ther 133: 108-115, 2012.
3. Soritau O, Tomuleasa C, Aldea M, Petrushev B, Susman S, Gheban D, Ioani H, Cosis A, Brie I, Irimie A, et al: Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas. J BUON 16: 282-289, 2011.
4. Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E and Schwab M: Metformin and cancer: From the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci 34: 126-135, 2013.
5. Campagnoli C, Abbà C, Ambroggio S, Brucato T and Pasanisi P: Life-style and metformin for the prevention of endometrial pathology in postmenopausal women. Gynecol Endocrinol 29: 119-124, 2013.
6. Ashburn TT and Thor KB: Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673-683, 2004.
7. Moiseeva O, Deschênes-Simard X, Pollak M and Ferbeyre G: Metformin, aging and cancer. Aging (Albany NY) 5: 330-331, 2013.
8. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R and Zinman B; American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193-203, 2009.
9. Bailey CJ: Biguanides and NIDDM. Diabetes Care 15: 755-772, 1992.
10. Bailey CJ and Turner RC: Metformin. N Engl J Med 334: 574-579, 1996.
11. Stumvoll M, Nurjhan N, Perriello G, Dailey G and Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333: 550-554, 1995.
12. Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE and Currie CJ: Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: A retrospective, observational study. Diabetes Obes Metab 16: 957-962, 2014.
13. Chan NN, Brain HP and Feher MD: Metformin-associated lactic acidosis: A rare or very rare clinical entity? Diabet Med 16: 273-281, 1999.
14. Kilo C: Metformin: A safe and effective treatment in the management of NIDDM. Mo Med 94: 114-123, 1997.
15. Vasisht KP, Chen SC, Peng Y and Bakris GL: Limitations of metformin use in patients with kidney disease: Are they warranted?. Diabetes Obes Metab 12: 1079-1083, 2010.
16. Horlen C, Malone R, Bryant B, Dennis B, Carey T, Pignone M and Rothman R: Frequency of inappropriate metformin prescriptions. JAMA 287: 2504-2505, 2002.
17. Calabrese AT, Coley KC, DaPos SV, Swanson D and Rao RH: Evaluation of prescribing practices: Risk of lactic acidosis with metformin therapy. Arch Intern Med 162: 434-437, 2002.
18. Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM and Krumholz HM: Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 290: 81-85, 2003.
19. Stang M, Wysowski DK and Butler-Jones D: Incidence of lactic acidosis in metformin users. Diabetes Care 22: 925-927, 1999.
20. Saydah SH, Loria CM, Eberhardt MS and Brancati FL: Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 157: 1092-1100, 2003.
21. Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA and Manson JE; Nurses' Health Study: Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 26: 1752-1758, 2003.
22. Will JC, Galuska DA, Vinicor F and Calle EE: Colorectal cancer: Another complication of diabetes mellitus? Am J Epidemiol 147: 816-825, 1998.
23. Everhart J and Wright D: Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273: 1605-1609, 1995.
24. Gapstur SM, Gann PH, Colangelo LA, Barron-Simpson R, Kopp P, Dyer A and Liu K: Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control 12: 763-772, 2001.
25. Moore MA, Park CB and Tsuda H: Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev 7: 89-107, 1998.
26. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305, 2005.
27. Bowker SL, Yasui Y, Veugelers P and Johnson JA: Glucose-lowering agents and cancer mortality rates in type 2 diabetes: Assessing effects of time-varying exposure. Diabetologia 53: 1631-1637, 2010.
28. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD and Evans JM: New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625, 2009.
29. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M and Cantley LC: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642-1646, 2005.
30. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226, 2008.
31. Inoki K, Li Y, Zhu T, Wu J and Guan KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-657, 2002.
32. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy. Gynecol Oncol 116: 92-98, 2010.
33. Stephenne X, Foretz M, Taleux N, van der Zon GC, Sokal E, Hue L, Viollet B and Guigas B: Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 54: 3101-3110, 2011.
34. Gunton JE, Delhanty PJ, Takahashi S and Baxter RC: Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab 88: 1323-1332, 2003.
35. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y and Bost F: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586, 2008.
36. Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638, 2003.
37. Navaratnarajah R, Pillay OC and Hardiman P: Polycystic ovary syndrome and endometrial cancer. Semin Reprod Med 26: 62-71, 2008.
38. Dronavalli S and Ehrmann DA: Pharmacologic therapy of polycystic ovary syndrome. Clin Obstet Gynecol 50: 244-254, 2007.
39. Dumesic DA and Lobo RA: Cancer risk and PCOS. Steroids 78: 782-785, 2013.
40. Zhou C, Gehrig PA, Whang YE and Boggess JF: Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther 2: 789-795, 2003.
41. Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y and Liao QP: Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 126: 113-120, 2011.
42. Tsuji K, Kisu I, Banno K, Yanokura M, Ueki A, Masuda K, Kobayashi Y, Yamagami W, Nomura H, Susumu N and Aoki D. Metformin: A possible drug for treatment of endometrial cancer. Open J Obstet Gynecol 2: 1-6, 2012.
43. Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA and Bae-Jump V: Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 132: 438-442, 2014.
44. Wolf I, Sadetzki S, Catane R, Karasik A and Kaufman B: Diabetes mellitus and breast cancer. Lancet Oncol 6: 103-111, 2005.
45. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE and Thor AD: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8: 2031-2040, 2009.
46. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8: 909-915, 2009.
47. Sachdev D, Singh R, Fujita-Yamaguchi Y and Yee D: Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: Implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 66: 2391-2402, 2006.
48. Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273, 2006.
49. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN and Gonzalez-Angulo AM: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297-3302, 2009.
50. Kim J, Lim W, Kim EK, Kim MK, Paik NS, Jeong SS, Yoon JH, Park CH, Ahn SH, Kim LS, et al: Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). BMC Cancer 14: 170, 2014.
51. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, et al: Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126: 215-220, 2011.
52. Iliopoulos D, Hirsch HA and Struhl K: Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71: 3196-3201, 2011.
53. Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R, Morgan M and Wheeler JE: Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol 152: 233-241, 2000.
54. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN and Bruchim I: In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 110: 246-250, 2008.
55. Bodmer M, Becker C, Meier C, Jick SS and Meier CR: Use of metformin and the risk of ovarian cancer: A case-control analysis. Gynecol Oncol 123: 200-204, 2011.
56. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H and Viberti G; ADOPT Study Group; RECORD Steering Committee: Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53: 1838-1845, 2010.
57. Zhang ZJ and Li S: The prognostic value of metformin for cancer patients with concurrent diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 16: 707-710, 2014.
58. Kumar S, Meuter A, Thapa P, Langstraat C, Giri S, Chien J, Rattan R, Cliby W and Shridhar V: Metformin intake is associated with better survival in ovarian cancer: A case-control study. Cancer 119: 555-562, 2013.
59. Pollak M: Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res (Phila) 3: 1060-1065, 2010.
60. Fogarty S and Hardie DG: Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 1804: 581-591, 2010.
61. Xiao X, He Q, Lu C, Werle KD, Zhao RX, Chen J, Davis BC, Cui R, Liang J and Xu ZX: Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol Oncol 127: 249-255, 2012.
62. Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Frimer M, Conroy E, Goldberg GL and Einstein MH: Metformin use and endometrial cancer survival. Gynecol Oncol 132: 236-240, 2014.
63. + breast cancer. Ann Oncol 23: 1771-1780, 2012.
64. Hou G, Zhang S, Zhang X, Wang P, Hao X and Zhang J: Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Res Treat 137: 807-816, 2013.
65. Peeters PJ, Bazelier MT, Vestergaard P, Leufkens HG, Schmidt MK, de Vries F and De Bruin ML: Use of metformin and survival of diabetic women with breast cancer. Curr Drug Saf 8: 357-363, 2013.
66. Xiao Y, Zhang S, Hou G, Zhang X, Hao X and Zhang J: Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer. Tumour Biol 35: 2035-2045, 2014.
67. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA and Lipscombe LL: Association between metformin therapy and mortality after breast cancer: A population-based study. Diabetes Care 36: 3018-3026, 2013.
68. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN and Gonzalez-Angulo AM: Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118: 1202-1211, 2012.
69. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA and Morgan CL: Mortality after incident cancer in people with and without type 2 diabetes: Impact of metformin on survival. Diabetes Care 35: 299-304, 2012.
70. Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S and Lengyel E: Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 119: 61-67, 2012.